Pancreatic Adenocarcinoma

NETs influence extracellular matrix remodeling and the T cell response to PDAC, allowing for a significant response to anti-PD-1 therapy. These findings support the combination therapy of immunotherapy and NET inhibition in patients with PDAC.

P1/2, N=150, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> May 2026

P2, N=40, Recruiting, Mayo Clinic | Trial completion date: May 2027 --> Jul 2029 | Trial primary completion date: May 2026 --> Jul 2029

P2, N=23, Completed, Emory University | Active, not recruiting --> Completed

The findings justify consideration of assessments of EBV status and tumor mutation burdens for patient stratification. Also, EBV-targeted immunotherapy for pancreatic adenocarcinoma may be considered for clinical trials.

P1/2, N=30, Recruiting, Clinica Universidad de Navarra, Universidad de Navarra

In xenograft models, CAR-T cells significantly prolonged median survival. Thus, UCB-derived anti-MSLN CAR-Ts showed reduced exhaustion, increased memory T cell proportions, and enhanced anti-tumor efficacy in vitro and in vivo.

This study represents one of the first translational investigations of IL-6/GP130/JAK/STAT3 signaling in pancreatic adenocarcinoma. By correlating molecular pathway activation with clinical and metabolic features, it will provide new insights into disease heterogeneity and support the development of personalized, pathway-targeted therapeutic strategies.

P1, N=56, Active, not recruiting, Legend Biotech USA Inc | Recruiting --> Active, not recruiting

Molecular testing is feasible and may even be more successful in cytologic smears than in biopsies or resections. High diagnostic yield and rapid processing favor their integration into routine molecular workflows. The superior performance of smears may relate to reduced stromal content and minimal processing delays. Cytologic specimens showed 100% DNA QC success, even when RNA QC failed, supporting their reliability. Although RNA analysis had a modest failure rate, its overall success suggests it can be incorporated into routine testing, particularly as fusion-driven targets gain clinical relevance.

Moreover, SOX5 was associated with genomic instability, susceptibility to medicines such as azacitidine and distinct mutation patterns. SOX5 suppression in NSCLC cells in vitro impeded proliferation, migration and invasion. These findings collectively emphasize the key function of SOX5 in tumor biology and highlight its potential as a biomarker for cancer diagnosis, prognosis and therapeutic targeting.